CAPR (Capricor Therapeutics) YoY EPS Growth: -22.81% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAPR Capricor Therapeutics Inc CAPR
27 GF Score
Price $6.29
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics YoY EPS Growth?

Capricor Therapeutics CAPR -7.91% 27 YoY EPS Growth is -22.81% as of Jun. 2026. GuruFocus rates CAPR with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Capricor Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 was -22.81%.

Capricor Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.70.

Capricor Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics YoY EPS Growth Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 -35.63 29.66 -38.55 -96.52

Capricor Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.86 -42.11 -287.50 -11.32 -22.81
CAPR
27GF Score
Capricor Therapeutics Inc CAPR
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Capricor Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-2.26--1.15)/ | -1.15 |
=-96.52 %

Capricor Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.7--0.57)/ | -0.57 |
=-22.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -22.81% mean?
Capricor Therapeutics (CAPR) has a YoY EPS Growth of -22.81% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' YoY EPS Growth too high?
Capricor Therapeutics' current YoY EPS Growth is -22.81%. Overall, Capricor Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' YoY EPS Growth compare to DRTS and SPTX?
Capricor Therapeutics' YoY EPS Growth of -22.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Capricor Therapeutics and its competitors. Capricor Therapeutics's current YoY EPS Growth is -22.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (CAPR) has a current YoY EPS Growth of -22.81%. The current YoY EPS Growth is -22.81%. Capricor Therapeutics' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current YoY EPS Growth is -22.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
27GF Score

Get the complete analysis for CAPR

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.29
Price